Versant Ventures Names New Operating Partner

Newport, California-based Versant Ventures said Friday that it has named James V. Mazzo as an operating partner. In his new position, Mazzo will focus on patient needs, new technology advancements and investment opportunities in the healthcare sector. He will also serve as chairman and CEO of AcuFocus, a Versant portfolio company. Previously, Mazzo was the CEO of Advanced Medical Optics and senior vice president of Abbott Labs.

PRESS RELEASE

Newport Beach, Calif. – July 12, 2013 – Versant Ventures, a leading venture capital firm, today announced that James V. (Jim) Mazzo, former CEO of Advanced Medical Optics (AMO) and Sr. VP of Abbott Labs, has joined the firm as Operating Partner.
Mazzo’s role will initially include three areas of responsibility. As Versant’s first Operating Partner based in Newport Beach, he will focus on patient needs, new technology advancements and investment opportunities in the healthcare field worldwide. In addition, he will serve as Chairman and CEO of AcuFocus, and as an advisor and board member to additional Versant portfolio companies. AcuFocus specializes in corneal inlays and is known for its revolutionary KAMRA inlay for the treatment of presbyopia.
William (Bill) Link, Versant Managing Director said, “We are very pleased to have Jim join the firm. His accomplishments and contribution to the healthcare industry as a successful CEO, and past president of AdvaMed, the U.S. medical devices association, and his global reputation as a leader in the healthcare industry, gives us great confidence in the value he will offer to our organization and portfolio companies.”
Jim Mazzo’s 35-year career in the healthcare industry includes seven years as Chairman, President and CEO of Advanced Medical Optics (AMO), which was sold to Abbott Labs in 2009 for $2.8 billion. He was previously with AMO’s parent company, Allergan, for over 20 years in a variety of expanding roles, working and living in the U.S., England, Italy and Canada. He led the spinoff of AMO from Allergan in 2002, expanding the business into a $1 billion industryleading, publicly-traded corporation. Since 2009, he has served as Senior Vice President, Abbott Laboratories and President, Abbott Medical Products, departing in May 2013 to join Versant.
Mazzo said, “My decision to join Versant is based on the firm’s successful track record in advancing medical innovation, revolutionizing patient care and improving quality of life. I am looking forward to working with Versant and its outstanding team of healthcare and investment Versant Ventures is a leading venture capital firm that invests in innovative, groundbreaking biopharmaceuticals, medical devices, and other life science opportunities. Founded in 1999, the firm consists of an experienced team committed to helping entrepreneurs build successful companies that impact healthcare and improve quality of life.

Related Posts

Leave a Reply

PEHUB Community

Join the 12501 members of peHUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

Psst! Got any hot tips?

  • This field is for validation purposes and should be left unchanged.

PE HUB News Briefs

RSS Feed Widget

Marketplace

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget

Reuters VC and PE feed

RSS Feed Widget